Table 9.

Neurochemical effects of developmental exposure to PBDEs

PBDE	Species	Treatment	Effect	Reference
BDE-47	C57BI/6 mice	6.8 mg/kg, oral in el/po, on PND10	Decrease GluR subunits NR2B, GluR1, CaMKII	Dingemans et al. 2007
BDE-99	NMRI mice	0.2,0.4,12.0 mg/kg oral, in el/po, on PND10	Decreased NR in hippocampus at 4 mo., only at 12 mg/kg	Viberg et al. 2004b
BDE-99	NMRI mice	12 mg/kg, oral in el/po, on PND10	On PND12 changes in a number of proteins in hippocampus, striatum (proteomics analysis)	Alm et al. 2006
BDE-99	Wistar rats	30 mg/kg, sc, in olive oil, GD2–9	Increase in cGMP, NMDA-stimulated cGMP, calmodulin , soluble GC alpha subunit. No change in nNOS	Llansola et al. 2007
BDE-153	NMRI mice	0.45, 0.9, 9.0 mg/kg, oral, in el/po, on PND10	Decreased NR in hippocampus on PND180 (9.0 mg/kg only)	Viberg et al. 2003a
BDE-209	NMRI mice	20.1 mg/kg, oral, in el/po, on PND3	Decreased BDNF, Gap-43, CaMKII at PND10, not at PND4	Viberg et al. 2007b (abstract)
DE-71	Ranch mink	0.01, 0.05, 0.25 mg/kg, in feed, GD0-PND42 (weaning)	No effects on MR, NR, AChE, ACh levels (PND 42, 190)	Bull et al. 2007

Abbreviations: el/po, egg lecithin/peanut oil; ACh, acetylcholine; AChE, acetylcholinesterase; MR, muscarinic receptors; NR, nicotinic receptors; GC, guanylate cyclase; nNOS, neuronal nitric oxide synthase.